Chlormethiazole 25 years: recent developments and historical perspectives: Proceedings of a Symposium in Stockholm, Sweden September 21‐22, 1985

Acta Psychiatrica Scandinavica

Volumn 73, Issue , 1986, Pages 1-158

  Evans, J G ^a   Feuerlein, W ^a   Glatt, M M ^a   Kanowski, S ^a   Scott, D B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84995205279     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1986.tb10515.x     Document Type: Article

References (230)

1. Positronkamerateknik visar hjärnans receptorfunktioner vid psykisk sjukdom
2. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography
3. Imaging of 11‐C labelled Ro 15‐1788 binding to benzodiazepine receptors in the human brain by positron emission tomography
4. Quantitative analysis of dopamine D‐2 receptor binding in the living human brain by positron emission tomography
5. Alpha‐adrenoceptors as central nervous system transmitters in the reduction of blood pressure
6. Anxiolytic action of clonidine
7. Effects of clonidine on anxiety disorders
8. Clonidine treatment of panic disorder
9. Clonidine blocks acute opiate withdrawal symptoms
10. Clonidine: Inpatient studies from 1978 to 1981
11. Clonidine in alcohol withdrawal
12. The use of clonidine in anxiety and withdrawal states
13. Clonidine Ameliorat Gilles de la Tourette Syndrome
14. Clonidine and Gilles de la Tourette Syndrome
15. Cigarette craving, smoking withdrawal and clonidine
16. Clonidine treatment of schizophrenia. Double‐blind comparison to placebo and neuroleptic drugs
17. Antimanic effect of clonidine
18. Memory enhancement in Korsakoff's psychosis by clonidine: Further evidence for a noradrenergic deficit
19. Evidence for a central noradrenaline receptor stimulation by clonidine
20. Involvement of alpha‐receptors in clonidine induced inhibition of transmitter release from central monoamine neurons
21. Inhibition of both noradrenergic and serotonergic neurons in brain by the alphaadrenergic agonist clonidine
22. Effects of antihypertensive and other drugs on central adrenaline utilization
23. Morphological and functional aspects of central monoamine neurons
24. On the significance of central noradrenaline for motor activity: experiments with a new dopamine beta‐hydroxylase inhibitor
25. Activity of norepinephrine‐con‐taining locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep‐waking cycle
26. Norepinephrine‐containing neurons in behaving rats exhibit pronounced responses to non‐noxious environmental stimuli
27. Nucleus locus coeruleus: New evidence of anatomical and physiological specificity
28. Alterations in the function of the nucleus locus coeruleus: a possible model for studies of anxiety
29. Central alpha‐adrenoceptors and affective symptoms and disorder
30. Autonomic and psychic effects of yohimbine hydrochlorise
31. Brain noradrenergic neurons in the locus coeruleus: inhibition by blood volume load through vagal afferents
32. Hypercapnia and hypoxia: Chemoreceptor mediated control of central norepinephrine neurons and splanchnic, sympathetic nerves
33. Regulation of Locus coeruleus neurons and splanchnic, sympathetic nerves by cardiovascular afferents
34. Organisation for physiological homeostasis
35. Control of behaviour and brain noradrenaline neurons by peripheral blood volume receptors
36. Activation of the sacral parasympathetic pathway to the urinary bladder by brain stem stimulation
37. Locus coeruleus region: Effects on behaviour of cholinergic, noradrenergic and opiate drugs injected intracerebrally into freely moving cats
38. The locus coeruleus: Neurobiology of a central noradrenergic nucleus
39. Descending projections of the locus coeruleus and subcoeruleus/medial parabrachial nuclei in monkey: Axonal transport studies and dopamine‐beta‐hydroxylase immunocytochemistry
40. Dopamine and noradrenaline receptor stimulation: Reversal of reserpineinduced suppression of motor activity
41. Adrenergic receptor blocking agents: Effects on central noradrenaline and dopamine receptors and on motor activity
42. Different alphaadrenoceptors in the central nervous system mediating biochemical and functional effects of clonidine and receptor blocking agents
43. Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response by clonidine
44. Dorsal noradrenergic bundle lesions fail to alter opiate withdrawal or suppression of opiate withdrawal by clonidine
45. Effects of lesion on the locus coeruleus and clonidine treatment on ethanol withdrawal syndrome in rats
46. Evidence for involvement of central NA neurons in alcohol intake. Increased alcohol consumption after degeneration of the NA pathway to the cortex cerebri
47. Alcohol intake and ethanol intoxication in the rat: effects of a 6‐OHOA induced lesion of the ascending noradrenaline pathways
48. Noradrenergic role in the self‐administration of ethanol
49. Noradrenergic mediation of the positive reinforcing properties of ethanol
50. Norepinephrine metabolism in the central nervous system of man. Studies using 3‐methoxy‐4‐hydroxy‐phenylethylene glycol levels in cerebrospinal fluid
51. Locus coeruleus stimulation increases noradrenergic metabolite levels in rat spinal cord
52. Peripheral correlates of central noradrenergic activity
53. Relation between plasma and cerebrospinal fluid levels of 3‐methoxy‐4‐hydroxyphenyl‐ethyleneglycol
54. Central norepinephrine metabolism during alcohol intoxication in addicts and healthy volunteers
55. Central nervous system noradrenaline metabolism and alcohol consumption in man
56. Central nervous noradrenaline metabolism in alcoholics during long‐term abstinence
57. Clinical conditions and concentrations of MOPEG in the cerebrospinal fluid and urine of alcoholic patients during withdrawal
58. Central norepinephrine metabolism during alcohol intoxication in man ‐ relationship to blood alcohol concentration
59. Simultaneous determination of the three major monoamine metabolites in brain tissue and body fluids by a mass fragmentographic method
60. Catecholamine derived compounds in urine and cerebrospinal fluid from alcoholics during and after long‐standing intoxication
61. 5‐hydroxy‐tryptophol in the cerebrospinal fluid and urine of alcoholics and healthy subjects
62. CSF levels of norepinephrine during alcohol withdrawal
63. Clonidine in alcohol withdrawal
64. Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism
65. The activity of monoamine oxidase‐A and ‐B in brains from chronic alcoholics
66. Altered mood and norepinephrine metabolism following withdrawal from alcohol
67. Monoamine metabolites in lumbar cerebrospinal fluid and urine in alcoholic patients before and after treatment with Disulfiram
68. Alteration in beta‐adrenergic receptor binding during ethanol withdrawal
69. Noradrenergic sensitivity of the cerebral cortex after chronic ethanol ingestion and withdrawal
70. Presynaptic modulation of beta‐adrenergic receptors in rat cerebral cortex after treatment with antidepressants
71. Alcoholism III. Diagnosis and familial psychiatric illness in 255 alcoholic probands
72. Depressive disease ‐ a genetic study
73. Opioid antagonists and deconditioning in addiction treatment in drug dependence ‐ treatment and treatment evaluation
74. Om medicinbehov och användning av aversionsmedel vid protraherad alkoholabstinens
75. Experimentally induced alcoholic hangover
76. Classification of alcohol withdrawal syndromes
77. Acute alcohol withdrawal syndromes
78. Delirium tremens. Some clinical features. Part II
79. Alcohol metabolism
80. The involvement of different central neurotransmitters in mediating stimulatory and sedative effects of ethanol
81. Endorphins in human cerebrospinal fluid during ethanol intoxication and withdrawal
82. Comparative aspects of tolerance to, and dependence on alcohol, barbiturates and opiates
83. Development of optimal treatment tactics for alcohol withdrawal. I: Assessment and effectiveness of supportive care
84. Empirical patterns of heroin consumption among selected street heroin users
85. Morphine and Morphine Substitutes
86. Recent Advances in the Pharmacology of Morphine like Drugs Dependence
87. Clonidine in opiate withdrawal
88. Opiate withdrawal using clonidine
89. The effects of alcohol on the nervous system
90. An experimental study of the etiology of “rum fits” and delirium tremens
91. Relationship of alcohol dose to intensity of withdrawal signs in mice
92. Induction of physical dependence upon ethanol and the associated behavioral changes in rats
93. Pharmacotherapy of acute and chronic alcoholism and alcohol withdrawal syndrome
94. Experimentally induced intoxication in alcoholics. A comparison between programed and spontaneous drinking
95. The acute alcohol withdrawal syndrome; findings and problems
96. Adrenal function and alcoholism. II. Catecholamines
97. Drug therapy of the alcohol withdrawal syndrome
98. System of Practical Medicine by American Authors
99. Veronalbehandling af delirium tremens
100. Delirium tremens and related clinical states. Aetiology, pathophysiology and treatment
101. Treatment of alcohol dependence; The alcoholic patient
102. The treatment of delirium tremens. Controversy in the literature
103. Importance of nonpharmacologic interventions in the treatment of acute alcohol withdrawal
104. Development of optimal treatment tactics for alcohol withdrawal. Assessment and effectiveness of supportive care
105. Detoxification of 1.024 alcoholic patients without psychoactive drugs
106. Nonpharmacological supportive care compared to chlomethiazole infusion in the management of severe acute alcohol withdrawal
107. Fatal chlomethiazole poisoning in chronic alcoholics
108. Place of chlomethiazole in treatment of alcoholics
109. Place of chlomethiazole in treatment of alcoholics
110. Ambulant treatment of alcohol withdrawal symptoms with carbamazepine. A formal multicentre double‐blind comparison with placebo
111. Anticonvulsive‐sedative treatment of delirium alcoholicum
112. Treatment of acute alcohol withdrawal syndrome with carbamazepine. A double‐blind comparison with tiapride
113. Treatment of alcohol withdrawal symptoms in hospitalized patients
114. A double‐blind comparison of carbamazepine and chlomethiazole in the treatment of alcohol withdrawal syndrome
115. Noradrenaline and adrenaline in the rat brain during acute and chronic administration and during withdrawal
116. Catecholamines and 5‐hydroxytryptamine in morphine tolerance and withdrawal
117. 2 receptors: light microscopic autoradiographic localization
118. Receptors for clonidine in brain: Insights into therapeutic actions
119. 2‐adrenoceptors and opiate receptors
120. Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha‐adrenergic agonist clonidine
121. Effects of clonidine on morphine withdrawal signs in the rat
122. A historical and biological overview: Brain transmitters, receptors, single cells, and a new treatment for opiate addiction
123. R (2‐(2,6‐dichlorphenyl‐amine)‐2‐imidazoline hydrochloride) in hypertensive patients
124. Dorsal noradrenergic bundle lesions fail to alter opiate withdrawal or suppression of opiate withdrawal by clonidine
125. Clonidine reversal of increased norepinephrine metabolite levels during morphine withdrawal
126. Clonidine suppression of noradrenergic hyperactivity during morphine withdrawal by clonidine: Biochemical studies in rodents and primates
127. Yohimbine exacerbates and clonidine attenuates acute morphine withdrawal in rats
128. The primate locus coeruleus and effects of clonidine on opiate withdrawal
129. Development of tolerance to the analgesic effect of clonidine in rats, cross‐tolerance to morphine
130. Antinociceptive activity of clonidine and its potentiation of morphine analgesia
131. 2 receptor‐mediated effects of clonidine
132. Abrupt discontinuation of tricyclic antidepressant drugs: Evidence of noradrenergic hyperactivity
133. Clonidine in opiate withdrawal
134. Clonidine blocks acute opiate‐withdrawal symptoms
135. Noradrenergic hyperactivity in opiate withdrawal supported by clonidine reversal of opiate withdrawal
136. Efficacy in opiate withdrawal: A study of thirty patients
137. The use of clonidin in detoxification from opiates
138. Opiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment
139. Clonidine suppresses the opioid abstinence syndrome without clonidin‐withdrawal symptoms: A blind inpatient study
140. Essai de la clonidine dans le sevrage des toxicomanies aux opiacés
141. Outpatient opiate detoxification with clonidine
142. Klonidin i abstinensbehandlingen af opiatmissbrugere
143. The clinical use of clonidine in abrupt withdrawal from methadone
144. Clonidine and naltrexone. A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy
145. Application de la clonidine au traitement de l'état de manque des toxicomanies opiacées
146. Clonidine therapy for narcotic withdrawal
147. Overall evaluation of treatment modalities for heroin addiction in a toxicology unit
148. Clonidin zur Behandlung der Heroinentzugsyndroms
149. Le sevrage des toxicomanies aux opiacés en hopital général
150. Clonidine hallucinations
151. Hyperadrenergic hypomania consequent to the abrupt cessation of clonidine
152. Interaction between clonidine and desipramine in man
153. Opiate detoxification with lofexidine
154. Opiate withdrawal using lofexidine, a clonidine analogue with fewer side effects
155. Clonidine in Alcohol Withdrawal
156. Cigarrette Craving, Smoking Withdrawal, and Clonidine
157. Clonidine Blocks Acute Withdrawal Symptoms
158. Klonidin ‐ nyt afgiftningsprincip ved opiatmisbrug
159. Psychotropic Actions of Clonidine
160. Clonidine Therapy for Tardive Dyskinesia and Related Syndromes
161. Farmakokinetik för karbamazepin hos alkoholister
162. The Clinical Use of Clonidine in Outpatient Detoxification from Opiates
163. Anxiolytic action of clonidine
164. Clonidine treatment of panic disorder
165. Nordadrenergic function in Panic Anxiety. Effects of Yohimbine in Healthy Sucjects and Patients with Agoraphobia and Panic Disorder
166. State Anxiety, Psysical Activity and Urinary 3‐Methoxy‐4‐Hydroxyphenethylene Glycol Excretion
167. Effects of clonidine on anxiety disorders
168. Extein J Clonidine: Inpatient studies from 1978 to 1981
169. Clonidine treatment of schizophrenia. Double blind comparison to placebo and neuroleptic drugs
170. Antimanic effect of clonidine
171. Clonidine Ameliorates Gilles de la Tourette Syndrome
172. Cigarette craving, smoking withdrawal and clonidine
173. Preliminary trial of the noradrenergic agonist clonidine in psychiatric patients
174. Neurolepticinduced supersensitivity psychosis: Clinical and pharmacological characteristics
175. A preliminary evaluation of the sedative effects of catapres, a new antihypertensive agent, in chronic schizophrenic patients
176. Effects of clonidine on morphine withdrawal signs in the rat
177. Depression by clonidine of shaking behaviour elicited by nalorphine in morphine dependent rats
178. Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine
179. Clonidine blocks acute opiate withdrawal symptoms
180. Effects of lesion of the locus coeruleus and clonidine treatment on ethanol withdrawal syndrome in rats
181. Clonidine in alcohol withdrawal
182. Efficacy of Clonidine in Treatment of Alcohol Withdrawal State
183. Clonidine Suppression of the Alcohol Withdrawal Syndrome
184. The measurement of mood
185. Clonidine treatment of schizophrenia. Double‐blind comparison to placebo and neuroleptic drugs
186. Parkinsonism provoked by alcoholism
187. Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha‐adrenergic agonist clonidine
188. The effect of clonidine and penbutolol, respectively on catecholamines in blood and urine, plasma renin activity and urinary aldosterone in hypertensive patients (1)
189. Prolonged clonidine treatment: Catecholamines, renin activity and aldosterone following exercise in hypertensives
190. Clonidine: Attenuation of sedative action by facilitated central noradrenergic neurotransmission
191. Bromocriptine in the treatment of the alcohol withdrawal syndrome
192. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine
193. A non‐chromatographic nonextraction radioimmunoassay for serum aldosterone
194. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects
195. Development of a RIA for clonidine and its comparison with the reference methods